U.S. Markets open in 3 hrs 29 mins

Sotera Health Company (SHC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.30+0.74 (+3.01%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.56
Open24.76
Bid0.00 x 800
Ask0.00 x 1200
Day's Range24.76 - 25.42
52 Week Range21.21 - 30.38
Volume497,762
Avg. Volume691,741
Market Cap7.157B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.44
  • GlobeNewswire

    Vivid Seats Announces Post-Merger Public Company Board of Directors

    Nominees Bring Strong Public Company Experience Ahead of Merger Completion David Donnini to Become Chairman of the Board CHICAGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vivid Seats Inc. (“Vivid Seats” or “the Company”), a leading marketplace that utilizes its technology platform to connect millions of fans with thousands of ticket sellers across hundreds of thousands of events each year, announced its proposed public company Board of Directors in its registration statement on Form S-4/A filed with th

  • Motley Fool

    Sotera Health Company (SHC) Q2 2021 Earnings Call Transcript

    This is Michelle, and welcome to the Sotera Health second-quarter 2021 results call. This webcast is being recorded and a replay will be available in the Investors section of the Sotera Health website. On the call today are Michael Petras, chairman and chief executive officer; and Scott Leffler, chief financial officer.

  • GlobeNewswire

    Sotera Health Reports Second-Quarter and First-Half 2021 Results; Increases 2021 Outlook

    Q2 2021 net revenues of $252 million increased approximately 18%, compared to Q2 2020Q2 2021 net income of $43 million or $0.15 per diluted share, compared to net income of $7 million or $0.03 per diluted share in Q2 2020Q2 2021 Adjusted EBITDA of $135 million increased approximately 18%, compared to Q2 2020Q2 2021 Adjusted EPS of $0.26 improved $0.12 compared to Q2 2020 Adjusted EPS of $0.14June 30, 2021 total debt of $1.9 billion and net debt of $1.7 billion; net leverage ratio improved to 3.8